Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1040 publications
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Journal: JAMA oncology
Published: September 25, 2025
Rethinking Ribociclib Dosage and Use in the Era of Patient-Centered Oncology-When Less Is More.
Journal: JAMA oncology
Published: September 25, 2025
600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial.
Journal: JAMA oncology
Published: September 25, 2025
Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer.
Journal: Journal of comparative effectiveness research
Published: August 29, 2025
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.
Journal: BMJ open
Published: August 27, 2025
Cardiovascular safety of CDK4/6 inhibitors in advance breast cancer: Assessing risks of QTc prolongation and thrombosis.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: August 20, 2025
Targeting CDK4 and CDK6 in hormone-dependent cancers.
Journal: Vitamins and hormones
Published: August 14, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 11, 2025
First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eligible population.
Journal: Journal of managed care & specialty pharmacy
Published: July 30, 2025
Impact of Body Composition on Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Ribociclib.
Journal: Current oncology (Toronto, Ont.)
Published: July 22, 2025
Last Updated: 10/31/2025